Classical and/or alternative NF-kappaB pathway activation in multiple myeloma

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Mutations in the nuclear factor-kappaB (NF-kappaB) pathway are found in a significant percentage of multiple myeloma (MM) tumors and cell lines.
• These mutations are associated with tumor progression and reduced dependence on bone marrow-derived signals for NF-kappaB activation.

Purpose of the Study:

• To clarify the mechanisms by which mutations in the NF-kappaB pathway operate in MM.
• To investigate the distinct roles of classical and alternative NF-kappaB activation pathways in MM.
• To understand the impact of these mutations on MM tumor autonomy.

Main Methods:

• Analysis of a panel of 51 MM cell lines (MMCLs) with mutations in the NF-kappaB pathway.
• Investigation of specific mutations (NFKB2, CYLD, NFKB1, TACI, NIK, TRAF2, TRAF3, cIAP1&2, CD40) and their effects on classical and alternative NF-kappaB activation.
• Confirmation of the roles of TRAF2 and TRAF3 in NF-kappaB-inducing kinase (NIK) degradation.
• Selective activation of classical or alternative NF-kappaB pathways via transfection to assess gene expression changes in MMCLs.

Main Results:

• NFKB2 mutation selectively activates the alternative pathway, while CYLD, NFKB1, and TACI mutations selectively activate the classical pathway.
• Most mutations affecting NF-kappaB-inducing kinase (NIK) levels activate the alternative pathway, and often both pathways.
• TRAF2 is critical for NIK degradation, and TRAF3 enhances but is not essential for NIK proteasomal degradation.
• Selective activation of either NF-kappaB pathway leads to similar gene expression changes in MMCLs, suggesting functional overlap.

Conclusions:

• Multiple myeloma tumors can gain autonomy from the bone marrow microenvironment through mutations activating either the classical or alternative NF-kappaB pathway.
• Understanding these pathways is crucial for developing targeted therapies for MM.